Table 4

 Incidence of adverse events ⩾5% of patients by treatment group

ETN (n = 159)ETN+MTX (n = 155)
ETN, etanercept; MTX, methotrexate.
*On the basis of number of adverse events rather than number of subjects; n = 317 for ETN; n = 365 for ETN+MTX.
Any adverse event, n (%)100 (62.9)109 (70.3)
Most common adverse events,n (%)
    Nasopharyngitis13 (8.2)20 (12.9)
    Headache14 (8.8)10 (6.5)
    Rheumatoid arthritis12 (7.5)11 (7.1)
    Injection-site reaction10 (6.3)10 (6.5)
    Arthralgia10 (6.3)5 (3.2)
    Injection-site erythema9 (5.7)5 (3.2)
    Cough4 (2.5)8 (5.2)
Any adverse event causing withdrawal, n (%)13 (8.2)9 (5.8)
Any serious adverse event,n (%)8 (5.0)7 (4.5)
Infections, n (%)39 (24.5)50 (32.3)
    Mild*38 (12.0)52 (14.2)
    Moderate*13 (4.1)11 (3.0)
    Severe*2 (0.6)1 (0.3)